RxDoctor Payments Data

George Wathen, MD

Internal Medicine · Waldorf, MDNPI 1861453284

Payments from drug & device makers

$8,432in general payments, 2019–2025

Across 498 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$867
  • AbbVie$845
  • AstraZeneca$770
  • Pfizer$710
  • Lilly USA, LLC$672
  • Amgen$525
  • plus $4K from 54 others

What the payments were for

  • Speaking & faculty fees$140%
  • Food & beverage$8,19397%
  • Education$2253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK65$867
AbbVie(2 entities)61$845
AstraZeneca39$770
Pfizer39$710
Lilly USA, LLC36$672
Amgen(2 entities)26$525
Novo Nordisk32$483
E.r. Squibb & Sons, L.L.C.18$392
Boehringer Ingelheim17$311
Bayer13$219
Merck10$163
Teva Pharmaceuticals USA, Inc.8$160
Sunovion Pharmaceuticals Inc.11$159
Sumitomo Pharma America, Inc.8$152
Biogen6$130
Adamas Pharmaceuticals, Inc.7$109
Takeda Pharmaceuticals U.S.A., Inc.7$107
Astellas Pharma US Inc6$106
Abbott5$105
Amarin Pharma, Inc.5$92
Vanda Pharmaceuticals Inc.4$81
Scilex Pharmaceuticals Inc.6$78
Eisai Inc.4$76
Johnson & Johnson5$69
Esperion Therapeutics, Inc.3$68
Biohaven Pharmaceuticals, Inc.4$68
UCB, Inc.4$67
Novartis4$58
Sanofi-aventis U.S. LLC3$55
Kowa Pharmaceuticals America, Inc.3$54
Hikma Pharmaceuticals USA3$48
Exact Sciences2$48
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$43
Biohaven Pharmaceutical Holding Company Ltd.2$42
Tactile Systems Technology Inc1$36
Otsuka America Pharmaceutical, Inc.2$36
Athena Bioscience, LLC2$35
Sanofi Pasteur Inc.2$28
Acadia Pharmaceuticals Inc1$24
Gilead1$23
IBSA Pharma Inc.1$22
Mylan Specialty L.p.1$21
Neurelis, Inc.1$21
Nabriva Therapeutics, PLC1$19
Smith+Nephew1$17
Hologic Sales And Service, LLC1$17
Amneal Pharmaceuticals LLC1$17
Almatica Pharma LLC1$16
Currax Pharmaceuticals LLC1$16
Arbor Pharmaceuticals, Inc.1$15
Lundbeck LLC1$15
Vistapharm, Inc.1$15
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$15
Nestle Healthcare Nutrition Inc.1$14
Verona Pharma, Inc.1$14
Acorda Therapeutics, Inc1$14
Collegium Pharmaceutical, Inc.1$13
Electromed, Inc.1$12
Antares Pharma, Inc.1$12
Melinta Therapeutics, LLC1$11

How this compares

$8,432 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$223,777
Medicare patients
775
Services billed
4,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$203,129
OzempicSemaglutide140$150,617
Trelegy ElliptaFluticasone/Umeclidin/Vilanter116$116,244
JardianceEmpagliflozin99$95,415
JanuviaSitagliptin Phosphate41$49,309
MounjaroTirzepatide37$43,302
TrulicityDulaglutide27$32,188
MyrbetriqMirabegron44$30,670
FarxigaDapagliflozin Propanediol36$28,429
EntrestoSacubitril/Valsartan19$17,778
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$15,407
GemtesaVibegron29$14,572
XareltoRivaroxaban17$13,095
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen270$11,380
Dexlansoprazole DrDexlansoprazole34$11,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$710$203,129235 claims
Novo NordiskOzempic$483$150,617140 claims
GSKTrelegy Ellipta, Breo Ellipta$867$124,136137 claims
Boehringer IngelheimJardiance$311$95,41599 claims
Lilly USA, LLCMounjaro, Trulicity$672$75,49064 claims
MerckJanuvia, Janumet$163$57,03354 claims
AstraZenecaFarxiga, Breztri Aerosphere$770$43,83554 claims
Astellas Pharma US IncMyrbetriq$106$30,67044 claims
NovartisEntresto$58$17,77819 claims
Sumitomo Pharma America, Inc.Gemtesa$152$14,57229 claims
AbbVieCreon, Synthroid$845$13,511134 claims
Johnson & JohnsonXarelto$69$13,09517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Waldorf

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →